leadf
logo-loader
RNS
viewIntelligent Ultrasound Group PLC

Intelligent Ultrasnd - Half-year Report

RNS Number : 2853V
Intelligent Ultrasound Group PLC
06 August 2020
 

6 August 2020

Intelligent Ultrasound Group plc

(the "Group" or the "Company" or "Intelligent Ultrasound")

 

Half Year Report

 

Intelligent Ultrasound (AIM: MED), the artificial intelligence (AI) based ultrasound software and simulation company, announces its unaudited half year results to 30 June 2020. Despite the global impact of Covid19, the Company reduced its EBITDA¹ loss to £1.2m (H1 2019: loss of £1.3m) on a reduced revenue of £2.5m (H1 2019: £3.1m) and continued to successfully progress the development of four AI software products. The Company also successfully raised £5.2m from new and existing shareholders in May 2020.

 

Financial Highlights

·     Generated revenue of £2.5m (H1 2019: £3.1m)

·     Reduction in SG&A costs limited the EBITDA loss for the period to £1.2m (H1 2019: loss of £1.3m)

·    Successful placing raising £5.2m in May 2020

·    Cash balance at 30 June 2020 of £10.1m (31 December 2019: £7.3m)

·    Net cash used in operating activities of £1.5m (H1 2019: £1.7m)

 

 

Operational and Recent Highlights

Clinical AI Division

·     First ScanNav AI image analysis software remains on track for 2021 revenue generation

·     Commercial discussions with a number of OEMs for ScanNav AnatomyGuide software continue

·     Post period end, CE regulatory paperwork for ScanNav AnatomyGuide, filed on 24 July 2020

·     Completed first AI models for the new ScanNav Lung/Covid19 image analysis software

·     Completed AI proof of concept for ScanNav Prostate image analysis software

 

Simulation Division

·    Covid19 module released on BodyWorks Eve simulator in March was offered free to existing customers and used to train frontline staff, especially in London (Nightingale Hospital) and New York (VA Harbor Healthcare)

·    Successfully minimised the impact of Covid19 despite the severe constraints on selling and marketing products into hospitals

·    Moved to a new warehouse facility in Caerphilly, providing larger manufacturing and distribution capacity for our all Group products

 

¹EBITDA is a non-GAAP measure defined as operating loss before depreciation, amortisation, and impairment

 

Riccardo Pigliucci, Chairman, commented: "This is clearly a volatile time for businesses in almost all regions of the world. We are pleased to have traded relatively well during the first wave of the pandemic, but it remains hard to predict sales with the current restrictions and the potential for a second wave of the virus, further limiting access to our customers and collaborators in hospitals around the world.

 

"However, despite these restrictions, the management remain confident that our strong cash position, combined with a growing ultrasound simulator product range and a stream of future clinical AI revenues that we anticipate will start generating revenues next year, should enable the Group to reach its profitability inflection point. We are grateful to our shareholders for their support and look forward to updating the market as we continue to increase value in the business."

 

 

 

 

Enquiries:

 

Intelligent Ultrasound Group plc

www.intelligentultrasound.com

Stuart Gall, CEO

Tel: +44 (0)29 2075 6534

Helen Jones, CFO

 

 

 

Cenkos Securities

Tel:  +44 (0)20 7397 8900

Giles Balleny/Cameron MacRitchie (Nominated Adviser)

 

Michael Johnson/Julian Morse (Corporate Broking)

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy/Paul McManus

Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893

         

 

 

About Intelligent Ultrasound (www.investors.intelligentultrasound.com)

Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.

 
Based in Cardiff in the UK and Atlanta in the US, the Group operates two divisions:


Intelligent Ultrasound Simulation Division

 

Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator.  To date nearly 900 simulators have been sold to over 500 medical institutions around the world.


Intelligent Ultrasound Clinical AI Division

 

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and ScanNav AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

 

Some products in the pipeline may require US FDA or other regulatory approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.

 

 

CHAIRMAN'S STATEMENT

 

I am pleased to present the Group's interim report for the six months ended 30 June 2020, during which we generated revenue of £2.5m (H1 2019: £3.1m) and importantly continued to progress development of four AI software products to market. All this was achieved during the global Covid19 lockdown, which has materially affected the reporting period and has dramatically constrained our ability to physically demonstrate and therefore sell ultrasound training simulators to hospitals around the world.

 

Review of the first six months of 2020

 

We set ourselves four main targets for 2020:

 

i)             bring our first ScanNav AI image analysis product to market

ii)            sign a second OEM agreement and commence regulatory filing for ScanNav AnatomyGuide

iii)           commence development of two new ScanNav products

iv)           continue the sales growth of the simulation division

 

The Covid19 pandemic caused the Board to revise the final target to that of minimising the impact of Covid19 on the simulation division's sales revenue and bottom line, as the Company's direct and reseller sales were effectively shut out of hospitals from March to June, dramatically constraining our ability to sell ultrasound training simulators to hospitals around the world.  Additionally, the Board decided to bring forward the 2021 placing to May 2020 to ensure that the Company maintains a strong cash position in these uncertain times. We remain on target to achieve all these targets by the year end.

 

Clinical AI Division

 

·     First ScanNav AI image analysis software remains on track for 2021 revenue generation

·     Commercial discussions with a number of OEMs for ScanNav AnatomyGuide software continue

·     Post period end, CE regulatory paperwork for ScanNav AnatomyGuide, filed on 24 July 2020

·     Completed first AI models for the new ScanNav Lung/Covid19 image analysis software

·     Completed AI proof of concept for ScanNav Prostate image analysis software

 

Our Clinical AI Division has continued to make significant progress in the period, even though the pandemic has restricted some access to doctors and trial patients and has delayed delivery of some new hardware components for AnatomyGuide.

The Group's first long-term licence and co-development agreement for its ScanNav AI software announced last year with one of the world's leading ultrasound equipment manufacturers remains on track for royalty per unit revenues during 2021. Terms of the agreement remain confidential and undisclosed for commercial reasons.

Discussions with a number of OEMs for the Group's second ScanNav AI software product, ScanNav AnatomyGuide continue and the CE regulatory paperwork for this product was filed on 24 July 2020. The FDA filing is expected to follow shortly, with approval and initial revenues anticipated in the second half of next year. The first version of the ScanNav AnatomyGuide AI software will, automatically and in real-time, identify and highlight structures such as nerves and arteries on the live ultrasound scan image that are important to be identified during Peripheral Nerve Block needling procedures.

A classroom-based version of ScanNav AnatomyGuide for pre-clinical teaching of clinicians is expected to be available for hospital training departments from the beginning of 2021. 

During the period the division has accelerated development of two additional AI software products. The first prototype models for the ScanNav Lung/Covid19 automated anomaly highlighting software and the ScanNav Prostate software were successfully completed. Early stage commercial discussions for these two products have commenced.

The Group intends to continue the fast track development of the Covid19 and Prostate AI-based software products in the second half of the year.

 

Simulation Division

 

·     Generated revenue for the Group of £2.5m (H1 2019: £3.1m)

·     Increased direct sales by 8% to £1.9m (H1 2019: £1.8m)

·     More than doubled sales in the UK to just under £1.0m (H1 2019: £0.5m)

 

The global Covid19 lockdown had most impact on the Group's simulation sales operations because both our direct and reseller sales were effectively shut out of hospitals from March to June, dramatically constraining our ability to sell ultrasound training simulators to hospitals around the world. With no access to hospitals, no trade exhibitions and sales teams confined to home, achieving revenue of £2.5m in the period, only 20% down on the comparative period (H1 2019: £3.1m), reflects the considerable efforts of the members of the division, given the worldwide impact of the pandemic.

Direct Sales

Revenue from our combined UK and North America direct sales operations increased by 8% to £1.9m (H1 2019: £1.8m), driven by an exceptional performance from the UK team who doubled sales to £0.96m (H1 2019: £0.45m) and surpassed their 2019 full year revenues of £0.7m

Over 50% of the UK sales were for the BodyWorks Eve simulator featuring the new Covid19 module. We are particularly proud to have produced this training module in record time in March at the start of the crisis and, by offering the module free to our customers, were able to play a significant role in training frontline staff, especially in London (Nightingale Hospital) and New York (VA Harbor Healthcare), in the fight against the virus.

However revenue generation in North America was affected by a Covid19 related freeze in discretionary spend that reduced sales by 29% to £0.9m (H1 2019: £1.3m). Although this is disappointing, after 2019 sales in the US had shown such good growth, we were pleased that sales of our obstetric training simulator, ScanTrainer, doubled in the period and we are optimistic that sales of the BodyWorks Eve simulator with the new Covid19 training module will help North America sales recover in the second half of the year.

Reseller Sales

Sales through resellers in China and Europe were the regions most affected by the impact of the pandemic with simulator revenues from the Rest of the World of just £0.59m for the six months to 30 June 2020 (H1 2019: £1.37m). This is a 57% decline on last year and reflects key countries such as China, France, Germany and Scandinavia being shut down for most of the trading period. Our resellers are working hard to rebuild sales in the second half of the year, as and when local restrictions in individual countries are lifted. 

Work environment

 

Across all of our locations, our staff have responded brilliantly to the Covid19 restrictions. Working from home our direct sales team have embraced remote methods of  selling our ultrasound training simulators to hospitals and our AI software development teams have continued to meet all our internal development milestones for the Group's new AI-based image analysis software. Development of our simulator product range has also continued, and the product build and technical support team expanded into a new warehouse facility in Caerphilly that will support the growth of both simulator and AI product sales as the Group grows over the coming years.

 

Some elements have been outside our control however and access to doctors and trial patients has inevitably caused some delay. Despite this we currently remain on target for first AI revenues in 2021, as planned.

 

 

 

Financial review

 

·     Generated revenue of £2.5m (H1 2019: £3.1m)

·     Reduction in SG&A costs limited the EBITDA loss for the period to £1.2m (H1 2019: loss of £1.3m)

·    Successful placing to raise £5.2m in May 2020

·    Cash balance at 30 June 2020 of £10.1m (31 December 2019: £7.3m)

·    Net cash outflow from operating activities of £1.5m (H1 2019: £1.7m)

 

Despite the 20% reduction in revenue compared to H1 2019, gross margin improved by 2% to 59% largely due to the increase in the proportion of direct sales generated in the period.

The reduction in gross profit has been offset by cost savings in selling, general and administrative expenses directly attributable to the impact of Covid19 restrictions relating to travel, exhibitions, and conferences. We also took the decision to close our second office in Oxford, temporarily freeze recruitment and limit external consultancy spend. In addition, our US sales office also received a US Paycheck Protection Program grant in May to cover two months of payroll and office expenses.

As a result of the above measures, the EBITDA loss for the six-month period was limited to £1.2m (H1 2019: £1.3m) with net cash outflow from operating activities at £1.5m, 13% lower than H1 2019 (£1.7m).

In May the Company undertook a successful share placing, raising £4.8m net of costs and as such cash at 30 June 2020 was £10.1m (31 December 2019: £7.3m, including short term deposits).

Outlook 

 

This is clearly a volatile time for businesses in almost all regions of the world. We are pleased to have traded relatively well during the first wave of the pandemic, but it remains hard to predict sales with the current restrictions and the potential for a second wave of the virus, further limiting access to our customers and collaborators in hospitals around the world.

 

However, despite these restrictions, the management remain confident that our strong cash position, combined with a growing ultrasound simulator product range and a stream of future clinical AI product revenues that we anticipate will start generating their first revenues next year, should enable the Group to reach its profitability inflection point.

 

 

Riccardo Pigliucci

Chairman

 

6 August 2020

 

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 

 

 

 

 

 

Notes

Unaudited

6 months ended

30 June

2020

Unaudited

6 months ended

30 June

 2019

Audited

year

ended

31 December

2019

 

 

 

 

 

 

 

£'000

£'000

£'000

 

 

 

 

 

REVENUE

4

2,479

3,117

5,916

Cost of sales

 

(1,018)

(1,335)

(2,462)

Gross profit

1,461

1,782

3,454

Other income

205

72

157

Administrative expenses

(3,616)

(3,847)

(8,169)

Total administrative costs

(3,411)

(3,775)

(8,012)

OPERATING LOSS

 

(1,950)

(1,993)

(4,558)

Finance income

 

17

-

-

Finance costs

 

(2)

(3)

(2)

LOSS BEFORE INCOME TAX

 

(1,935)

(1,996)

(4,560)

Taxation

5

116

45

337

LOSS ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE PARENT

 

 

(1,819)

 

(1,951)

 

(4,223)

 

 

 

 

 

OTHER COMPREHENSIVE INCOME/(LOSS)

 

 

 

 

Items that will or may be reclassified to profit or loss:

 

 

 

 

Exchange gain/(loss) arising on translation of foreign operations

 

 

50

 

8

 

(33)

OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD

 

50

8

(33)

 

 

 

 

 

TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE PARENT

 

 

(1,769)

 

(1,943)

 

(4,256)

 

 

 

 

 

LOSS PER ORDINARY SHARE (PENCE) ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE PARENT

Basic and diluted

6

 

 

(0.76)p

 

 

(1.25)p

 

 

(2.37)p

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 

 

Share capital

Share

warrants

Accumulated losses

Share-based payment

reserve

Foreign exchange reserve

Total equity attributable

 to shareholders

 

£'000

£'000

£'000

£'000

£'000

£'000

Balance as at 31 December 2018

1,566

126

(15,854)

562

21

9,396

Impact of IFRS16

-

-

2

-

-

2

At 1 January 2019 as restated

1,566

16,437

126

(15,852)

562

6,538

21

9,398

 

 

 

 

 

 

 

Comprehensive income for the period

 

 

 

 

 

 

Loss for the period

-

-

(1,951)

-

8

(1,943)

Transactions with owners, recorded directly in equity

 

 

 

 

 

 

 

Share-based payments

-

-

-

-

65

-

-

65

 

 

-

 

-

 

-

 

-

 

65

 

-

 

-

 

65

 

 

 

 

 

 

 

Balance as at 30 June 2019

1,566

 

16,437

126

(17,803)

627

6,538

29

7,520

 

 

 

 

 

 

 

 

Comprehensive income for the period

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

(2,272)

-

-

(41)

(2,313)

Transactions with owners, recorded directly in equity

 

 

 

 

 

 

 

 

Shares issued for cash

634

5,703

-

-

-

-

-

6,337

Cost of raising finance

-

(487)

-

-

-

-

-

(487)

Share-based payments

 

 

-

-

61

-

-

61

 

 

634

 

5,216

 

-

 

-

 

61

 

-

 

-

 

5,911

 

 

 

 

 

 

 

 

 

Balance as at 31 December 2019

2,200

21,653

126

(20,075)

688

6,538

(12)

11,118

 

 

 

 

 

 

 

 

 

Comprehensive income for the period

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

(1,819)

-

-

50

(1,769)

Transactions with owners, recorded directly in equity

 

 

 

 

 

 

 

 

Shares issued for cash

494

4,658

-

-

-

-

-

5,152

Cost of raising finance

-

(352)

-

-

-

-

-

(352)

Share-based payments

-

-

-

-

72

-

-

72

 

 

494

 

4,306

 

-

 

-

 

72

 

-

 

-

 

4,872

 

 

 

 

 

 

 

 

 

Balance at 30 June 2020

2,694

25,959

126

(21,894)

760

6,538

38

14,221

 

 

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 

 

Note

Unaudited

30 June 2020

Unaudited

30 June 2019

(restated)

Audited

31 December

2019

 

 

 

 

 

 

 

£'000

£'000

£'000

NON-CURRENT ASSETS

 

 

 

 

Intangible assets

  7 

2,148

2,668

2,332

Property, plant and equipment

    

670

479

545

 

2,818

3,147

2,877

CURRENT ASSETS

 

 

 

Inventories

    

1,293

497

663

Trade and other receivables

    

2,073

2,611

2,700

Current tax asset

 

131

-

148

Investments (short term deposits)

 

-

-

5,500

Cash and cash equivalents

 

10,137

3,481

1,790

 

13,634

6,589

10,801

TOTAL ASSETS

16,452

9,736

13,678

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

Trade and other payables

     8

(1,216)

(1,302)

(1,670)

Deferred income

 

(287)

(179)

(325)

Income tax

 

-

(100)

-

Lease liabilities

 

(66)

(14)

(53)

Provisions

    

(98)

(85)

(95)

 

(1,667)

(1,680)

(2,143)

 

 

 

 

NON-CURRENT LIABILITIES

 

 

 

Deferred income

(211)

(187)

(109)

Deferred taxation

(265)

(333)

(288)

Lease liabilities

(88)

(16)

(20)

 

(564)

(536)

(417)

TOTAL LIABILITIES

(2,231)

(2,216)

(2,560)

NET ASSETS

14,221

7,520

11,118

 

  EQUITY

 

 

 

 

  Share capital

9

2,694

1,566

2,200

  Share premium

 

25,959

16,437

21,653

  Share warrants

 

126

126

126

  Accumulated losses

 

(21,894)

(17,803)

(20,075)

  Share-based payment reserve

 

760

627

688

  Merger reserve

 

6,538

6,538

6,538

  Foreign exchange reserve

 

38

29

(12)

 TOTAL EQUITY

 

14,221

7,520

11,118

 

 

 

CONSOLIDATED STATEMENT OF CASH FLOWS

 

 

 

Unaudited

 6 months ended

30 June 2020

Unaudited

6 months

 ended

30 June 2019

Audited

year ended

31 December 

2019

 

 

 

£'000

£'000

£'000

 

 

CASH FLOW FROM CONTINUING OPERATING ACTIVITIES

 

 

 

 

 

 

Loss before tax

(1,935)

(1,996)

(4,560)

 

 

Add back:

 

 

 

 

 

Depreciation

171

115

334

 

 

Amortisation of intangible assets

476

525

1,040

 

 

Foreign exchange

47

-

-

 

 

Increase in warranty provision

4

-

-

 

 

Research and development expenditure credit

(38)

-

-

 

 

Finance income

(17)

-

-

 

 

Finance costs

2

-

2

 

 

Share-based payments expense

72

65

126

 

 

Operating cash flows before movement in working capital

(1,218)

(1,291)

(3,058)

 

 

Movement in inventories

(630)

354

188

 

 

Movement in trade and other receivables

627

(697)

(787)

 

 

Movement in trade and other payables

(410)

(130)

283

 

 

Cash used in operations

(1,631)

(1,764)

(3,374)

 

 

Income taxes received

168

80

80

 

 

 

NET CASH USED IN OPERATING ACTIVITIES

 

(1,463)

 

(1,684)

(3,294)

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

Purchase of property, plant and equipment

(292)

(144)

(355)

 

Disposal of property, plant and equipment

-

-

12

 

Interest receivable

17

-

-

 

Movement in short term deposits

5,500

-

(5,500)

 

Internally generated and purchase of intangible assets

(193)

(306)

(485)

 

 

NET CASH GENERATED FROM/(USED IN) INVESTING ACTIVITIES

5,032

(450)

(6,328)

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

Issue of new shares

5,152

-

6,337

 

 

Share issue costs

(352)

-

(487)

 

 

Principal elements of lease payments

(23)

-

(37)

 

 

Finance costs paid

(2)

-

(2)

 

 

NET CASH GENERATED FROM FINANCING ACTIVITIES

4,775

-

5,811

 

 

 

NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS

8,344

(2,134)

(3,811)

 

 

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

1,790

5,607

5,607

 

 

Exchange gains/(losses) on cash and cash equivalents

3

8

(6)

 

 

CASH AND CASH EQUIVALENTS AT END OF PERIOD

10,137

3,481

1,790

 

               
 

 

 

NOTES TO THE CONSOLIDATED INTERIM REPORT

for the six months ended 30 June 2020

 

1.     BASIS OF PREPARATION AND ACCOUNTING POLICIES

 

The financial information contained in this interim report has not been audited by the Group's auditor and does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006.  The Directors approved and authorised this interim report on 5 August 2020.  The financial information for the preceding full year is extracted from the statutory accounts for the financial year ended 31 December 2019.  Those accounts, upon which the auditor issued an unqualified opinion and did not include a statement under Section 498(2) or (3) of the Companies Act 2006, have been delivered to the Registrar of Companies.

 

This interim report has been prepared in accordance with UK AIM Rules for Companies.  The Group has not applied IAS 34 "Interim Financial Reporting" (which is not mandatory for UK Groups) in the preparation of this interim report.  The interim report has been prepared in a manner consistent with the accounting policies set out in the statutory accounts for the financial year ended 31 December 2019, except for the following:

-    Foreign exchange differences arising on the retranslation of the sterling loan in the US subsidiary, IUNA has been recognised in the foreign exchange reserve.

 

The Company is a limited liability company incorporated and domiciled in England & Wales and whose shares are quoted on AIM, a market operated by The London Stock Exchange.  The Group financial statements are presented in pounds Sterling.

 

Impact of Covid19

 

The Group has considered the impact of Covid19 with respect to all judgements and estimates it makes in the application of its accounting policies. This included assessing the recoverability of trade receivables and inventory. There has been no significant deterioration in the ageing of trade receivables in the period. As a result of these reviews, there was no increase in the impairment losses for trade receivables or inventory provisions. The Group also assessed non-financial assets for indicators of impairment. No impairments were identified.

 

Going concern

 

As the Covid19 crisis unfolded, the Group promptly modelled a number of reduced revenue scenarios that, combined with operational cost savings, would not compromise the long-term prospects of the business. With much of the business devoted to the development of new AI-based image analysis software, reducing R&D staff costs through either redundancy or furlough was considered to have a detrimental impact on the development of these products and with the Group already running a lean sales operation for its simulation division, reducing staff would have impacted the Group's ability to generate sales revenue.  The business has therefore focussed on reducing marketing, shipping and operational costs as well as in May raising £4.8m (net of transaction costs) through a successful Placing from existing shareholders, which ensures the Group has sufficient cash reserves to continue to trade for at least the next 15 months, as well as continuing to be debt-free. Having assessed the principal risks facing the Group, together with the Group's forecasts and significant financial headroom, the Directors believe that the Group is well placed to manage these risks successfully and have a reasonable expectation that the Group has adequate resources to continue to successfully operate for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the interim financial statements.

 

 

 

 

2.     BASIS OF CONSOLIDATION

 

The consolidated interim report incorporates the results of the Company and its subsidiary undertakings.

 

Restatement of comparatives

 

Share warrants in the June 2019 comparative balance sheet have been reclassified. The consideration for the acquisition of IUL on 6 October 2017 included 837,795 share warrants with a fair value of £125,669 which were issued on completion of the acquisition. The terms of the warrant instrument agreement allow the holder to subscribe for a fixed number of shares in the Company at any time until 10 July 2021 for a fixed subscription price. In accordance with IAS 32 'Financial Instruments: Presentation', a contract that will be settled by the entity delivering a fixed number of its own equity instruments in exchange for a fixed amount of cash or another financial asset is an equity instrument. At 31 December 2017, these warrants had been classified as a financial liability but following a review of the accounting treatment these have been correctly reclassified to equity.

 

The June 2019 comparative balance sheet has also been restated for the adoption of IFRS 16 'Leases' consistent with the opening balances restated in the consolidated accounts as at 31 December 2019.

 

3.     NEW ACCOUNTING STANDARDS

 

Several amendments and interpretations apply for the first time in 2020, but do not have an impact on the interim condensed consolidated financial statements of the Group.

 

4.     REVENUE ANALYSIS

 

The following table provides an analysis of the Group's revenue by type (Distribution or Direct Sales) and geography based upon location of the Group's customers. 

 

Unaudited 6 months ended 30 June 2020

Simulation Division

Clinical AI

Division

Total

 

Distribution

£'000

Direct Sales

£'000

 

£'000

 

£'000

United Kingdom

-

959

-

959

North America

-

929

-

929

Rest of World

591

-

-

591

 

591

1,888

-

2,479

 

 

Unaudited 6 months ended 30 June 2019

Simulation Division

Clinical AI

Division

Total

 

Distribution

£'000

Direct Sales

£'000

 

£'000

 

£'000

United Kingdom

-

450

-

450

North America

-

1,301

-

1,301

Rest of World

1,366

-

-

1,366

 

1,366

1,751

-

3,117

 

 

 

4.     REVENUE ANALYSIS (continued)

 

Audited year ended 31 December 2019

Simulation Division

Clinical AI

Division

Total

 

Distribution

£'000

Direct Sales

£'000

 

£'000

 

£'000

United Kingdom

-

721

-

721

North America

-

2,579

-

2,579

Rest of World

2,616

-

-

2,616

 

2,616

3,300

-

5,916

 

5.     TAXATION ON ORDINARY ACTIVITIES

 

 

Unaudited

 6 months ended 30 June 2020

 

£'000

Unaudited

6 months ended 30 June 2019

 

£'000

Audited

year ended

31 December 2019

£'000

 

 

 

 

R&D tax credit

(93)

-

(167)

Adjustment for over-claim of R&D tax credit in prior periods

 

-

 

-

 

(80)

Deferred tax credit

(23)

(45)

(90)

 

(116)

(45)

(337)

6.     LOSS PER SHARE

 

 

 

 

 

Unaudited

 6 months ended 30 June 2020

 

£'000

Unaudited

6 months ended 30

 June 2019

 

£'000

Audited

year ended

31 December 2019

£'000

Loss for the purposes of basic and diluted loss per share (LPS) being the loss attributable to the equity shareholders of the Company

 

 

(1,819)

 

 

(1,951)

 

 

(4,223)

 

Number of shares:

 

No.

 

No.

 

No.

 

Weighted average number of Ordinary shares for the purpose of basic LPS

 

 

240,082,506

 

 

156,627,749

 

 

178,503,090  

 

In the periods ended 30 June 2020, 30 June 2019 and 31 December 2019 there were share options in issue which could potentially have a dilutive impact, but as the Group was loss making they were anti-dilutive for each period and therefore the weighted average number of ordinary shares for the purpose of the basic and dilutive loss per share were the same.

 

 

7.      INTANGIBLE ASSETS

 

The net book value of intangible assets at 30 June 2019 includes intellectual property and brands acquired with IML and IUL totalling £1,393,753 (31 December 2019: £1,640,317 30 June 2019: £1,888,014).  The remaining net book value of intangible assets in each period were made up of development costs capitalised. 

 

8.      CURRENT LIABILITIES - TRADE AND OTHER PAYABLES

 

 

Unaudited

 30 June 2020

 

£'000

Unaudited

30 June 2019

 

£'000

Audited

31 December 2019

£'000

 

 

 

 

Trade payables

498

420

716

Taxation and social security

23

78

81

Accruals

640

721

764

Warrants

40

40

40

Other

15

43

69

 

1,216

1,302

1,670

 

9.  SHARE CAPITAL

 

 

Allotted, issued and fully paid:

No.

£'000

Ordinary shares of 1p each

 

 

Balance at 30 June 2019

156,627,749

1,566

Shares issued for cash

63,369,043

634

Balance at 31 December 2019

219,996,792

2,200

Shares issued for cash

49,400,000

494

Balance at 30 June 2020

269,396,792

2,694

 

On 17 April 2020 the Company placed 49,400,000 newly issued shares of 1 pence each in the capital of the Company at a price of 10.5 pence per share.  Share issue costs of £352k have been netted off against the share premium arising on the new share issue.

 

10.     INTERIM ANNOUNCEMENT

 

A copy of this report will be posted on the Company's website at www.intelligentultrasound.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IR BLGDIRSGDGGU

Quick facts: Intelligent Ultrasound Group PLC

Price: 15

Market: AIM
Market Cap: £40.41 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

39 min read